SINGAPORE: The updated JN.1 Novavax/Nuvaxovid COVID-19 vaccine will be offered under the national vaccination programme at selected Healthier SG general practitioner (GP) clinics until Apr 30.

Getting a COVID-19 vaccine or booster is similar to getting other vaccines and does not require any specific preparation. However, you can take some steps to reduce side effects and improve ...

shares of this vaccine maker have returned +3.5%, compared to the Zacks S&P 500 composite's +2.1% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Novavax ...

Hospitalizations and general "syndromic" cases were at 10+ statewide for the week. The number of reported COVID cases ...

The first human bird flu death in the US has Moderna's vaccine development in focus for investors this week. Recently, Zacks.com users have been paying close attention to Novavax (NVAX).

Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains. The average of price targets set by Wall Street analysts indicates a potential upside ...

The first inactivated influenza vaccine was monovalent (influenza A). In 1942, a bivalent vaccine was produced after the discovery of influenza B. It was later discovered that influenza viruses ...

Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines. From COVID-19 to malaria ...

Novavax’s COVID-19 vaccine produced higher levels of neutralising antibodies than produced by recovered patients in an early trial, paving the way for a phase 3 trial and potential approval by ...

Shares of Novavax (NVAX) have gained 3.5% over the past four weeks to close the last trading session at $8.81, but there could still be a solid upside left in the stock if short-term price targets ...

24, 2025 — A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical ...